Cancer targeted therapy strategy: The pathologist’s perspectives

Lara Alessandrini, Tiziana Perin, Shahin Kadarè, Lino Del Pup, Lorenzo Memeo, Agostino Steffan, Lorenzo Colarossi, Massimiliano Berretta, Paolo De Paoli, Vincenzo Canzonieri

Research output: Contribution to journalReview article

Abstract

The effectiveness of new personalized treatment procedures in oncology is based on the fact that certain tumors exhibit specific molecular features. More in detail, neoplastic tissues of patients should display a specific biomarker, most often a specific genetic alteration and/or under/overexpression of a definite protein, that could be the target of its respective drug. Immunohistochemical and molecular analyses, which usually include examination of nucleic acids from either tissues or fluids, are common tests to define the status of a tumor. This review focuses on the pathologist’s role in carefully controlling pre-analytic procedures and standard operating procedures that are a crucial prerequisite to reach reliable and reproducible results. Six paradigmatic applications of targeted therapy, for which pathological diagnosis plays a fundamental role, are summarized. Traditional and next-generation sequencing are also addressed from the pathologist’s perspective as well as the importance pathologists have in this shift to more accurate definition of disease risk and prognostication of therapy response in the personalized medicine era.

Original languageEnglish
Pages (from-to)410-420
Number of pages11
JournalCurrent Cancer Drug Targets
Volume18
Issue number5
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Neoplasms
Precision Medicine
Nucleic Acids
Therapeutics
Biomarkers
Pharmaceutical Preparations
Pathologists
Proteins

Keywords

  • Biomarker
  • FFPE tissue
  • Immunohistochemistry
  • Molecular analyses
  • Next-generation sequencing
  • Pathologist’s perspective
  • Target therapy
  • Traditional sequencing
  • Cancer targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

Cancer targeted therapy strategy : The pathologist’s perspectives. / Alessandrini, Lara; Perin, Tiziana; Kadarè, Shahin; Del Pup, Lino; Memeo, Lorenzo; Steffan, Agostino; Colarossi, Lorenzo; Berretta, Massimiliano; De Paoli, Paolo; Canzonieri, Vincenzo.

In: Current Cancer Drug Targets, Vol. 18, No. 5, 01.01.2018, p. 410-420.

Research output: Contribution to journalReview article

Alessandrini, Lara ; Perin, Tiziana ; Kadarè, Shahin ; Del Pup, Lino ; Memeo, Lorenzo ; Steffan, Agostino ; Colarossi, Lorenzo ; Berretta, Massimiliano ; De Paoli, Paolo ; Canzonieri, Vincenzo. / Cancer targeted therapy strategy : The pathologist’s perspectives. In: Current Cancer Drug Targets. 2018 ; Vol. 18, No. 5. pp. 410-420.
@article{df785289a8404a2c98cee72a01e7b716,
title = "Cancer targeted therapy strategy: The pathologist’s perspectives",
abstract = "The effectiveness of new personalized treatment procedures in oncology is based on the fact that certain tumors exhibit specific molecular features. More in detail, neoplastic tissues of patients should display a specific biomarker, most often a specific genetic alteration and/or under/overexpression of a definite protein, that could be the target of its respective drug. Immunohistochemical and molecular analyses, which usually include examination of nucleic acids from either tissues or fluids, are common tests to define the status of a tumor. This review focuses on the pathologist’s role in carefully controlling pre-analytic procedures and standard operating procedures that are a crucial prerequisite to reach reliable and reproducible results. Six paradigmatic applications of targeted therapy, for which pathological diagnosis plays a fundamental role, are summarized. Traditional and next-generation sequencing are also addressed from the pathologist’s perspective as well as the importance pathologists have in this shift to more accurate definition of disease risk and prognostication of therapy response in the personalized medicine era.",
keywords = "Biomarker, FFPE tissue, Immunohistochemistry, Molecular analyses, Next-generation sequencing, Pathologist’s perspective, Target therapy, Traditional sequencing, Cancer targeted therapy",
author = "Lara Alessandrini and Tiziana Perin and Shahin Kadar{\`e} and {Del Pup}, Lino and Lorenzo Memeo and Agostino Steffan and Lorenzo Colarossi and Massimiliano Berretta and {De Paoli}, Paolo and Vincenzo Canzonieri",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1568009618666171129145703",
language = "English",
volume = "18",
pages = "410--420",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Cancer targeted therapy strategy

T2 - The pathologist’s perspectives

AU - Alessandrini, Lara

AU - Perin, Tiziana

AU - Kadarè, Shahin

AU - Del Pup, Lino

AU - Memeo, Lorenzo

AU - Steffan, Agostino

AU - Colarossi, Lorenzo

AU - Berretta, Massimiliano

AU - De Paoli, Paolo

AU - Canzonieri, Vincenzo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The effectiveness of new personalized treatment procedures in oncology is based on the fact that certain tumors exhibit specific molecular features. More in detail, neoplastic tissues of patients should display a specific biomarker, most often a specific genetic alteration and/or under/overexpression of a definite protein, that could be the target of its respective drug. Immunohistochemical and molecular analyses, which usually include examination of nucleic acids from either tissues or fluids, are common tests to define the status of a tumor. This review focuses on the pathologist’s role in carefully controlling pre-analytic procedures and standard operating procedures that are a crucial prerequisite to reach reliable and reproducible results. Six paradigmatic applications of targeted therapy, for which pathological diagnosis plays a fundamental role, are summarized. Traditional and next-generation sequencing are also addressed from the pathologist’s perspective as well as the importance pathologists have in this shift to more accurate definition of disease risk and prognostication of therapy response in the personalized medicine era.

AB - The effectiveness of new personalized treatment procedures in oncology is based on the fact that certain tumors exhibit specific molecular features. More in detail, neoplastic tissues of patients should display a specific biomarker, most often a specific genetic alteration and/or under/overexpression of a definite protein, that could be the target of its respective drug. Immunohistochemical and molecular analyses, which usually include examination of nucleic acids from either tissues or fluids, are common tests to define the status of a tumor. This review focuses on the pathologist’s role in carefully controlling pre-analytic procedures and standard operating procedures that are a crucial prerequisite to reach reliable and reproducible results. Six paradigmatic applications of targeted therapy, for which pathological diagnosis plays a fundamental role, are summarized. Traditional and next-generation sequencing are also addressed from the pathologist’s perspective as well as the importance pathologists have in this shift to more accurate definition of disease risk and prognostication of therapy response in the personalized medicine era.

KW - Biomarker

KW - FFPE tissue

KW - Immunohistochemistry

KW - Molecular analyses

KW - Next-generation sequencing

KW - Pathologist’s perspective

KW - Target therapy

KW - Traditional sequencing

KW - Cancer targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85048975117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048975117&partnerID=8YFLogxK

U2 - 10.2174/1568009618666171129145703

DO - 10.2174/1568009618666171129145703

M3 - Review article

AN - SCOPUS:85048975117

VL - 18

SP - 410

EP - 420

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 5

ER -